This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bear Stalking Biotech Sector

The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.

Mark Schoenebaum, a biotech analyst with Bear Stearns, cautioned Tuesday that on the basis of his research, he expects the sector's performance to be flat through the end of the year.

For the 20 trading days in July, biotech stock indices gained more than 10%. Among individual issues, Amgen (AMGN - Get Report) was up 31%, Genentech (DNA) rose 10% and Genzyme (GENZ) jumped 25%.

According to Schoenebaum, historical trends indicate that "the biotech sector is unlikely to suffer a major correction over the next 3-6 months." But at the same time, the "data also indicate that another significant rally is unlikely this year," Schoenebaum wrote in a research note dated Aug. 1. He believes the sector "could remain range-bound" for the rest of the year.

Along with his colleagues, Schoenebaum, whose firm does and seeks to do business with the companies it covers, looked at the seven other instances when the Nasdaq and American Stock Exchange biotech indices were each up 10% or more for a 20-day period. Then they examined the performance of the component companies one month, three months and six months after those rallies.

Given his second-half assessment, the analyst recommends that investors dump the "basket approach" to the sector and take a closer look at individual companies' products, pipelines, sales and risks.

Finding Favorites

Looking at the earnings reported in the second quarter, this year's collective upside surprise from the combined results of three big biotechs was the largest it's been since 1999, Schoenebaum says in his research report.

Taken together, earnings from Amgen, Genentech and Genzyme were 16.25% more than consensus estimates, compared with 16.08% in the third quarter of 1999.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NABI $10.80 0.00%
IDIX $24.50 0.20%
AMGN $158.30 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs